CoChat

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Open access
Nilsson, Monique B., Yang, Yan, Heeke, Simon, Patel, Sonia A., Poteete, Alissa, Udagawa, Hibiki, Elamin, Yasir Y., Moran, Cesar A., Kashima, Yukie, Arumugam, Thiruvengadam, Yu, Xiaoxing, Ren, Xiaoyang, Diao, Lixia, Shen, Li, Wang, Qi, Zhang, Minying, Robichaux, Jacqulyne P., Shi, Chunhua, Pfeil, Allyson N., Tran, Hai, Gibbons, Don L., Bock, Jason, Wang, Jing, Minna, John D., Kobayashi, Susumu S., Le, Xiuning, Heymach, John V. · 2023 · Cancer Cell
Cited by 106

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Summary Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) mediated by epithelial to mesenchymal transition (EMT). We investigate cell surface proteins that could be targeted by antibody-based or adoptive cell therapy approaches and identify CD70 as being highly upregulated in EMT-associated resistance. Moreover, CD70 upregulation is an early event in the evolution of resistance and occurs in drug-tolerant persister cells (DTPCs). CD70 promotes cell survival and invasiveness, and stimulation of CD70 triggers signal transduction pathways known to be re-activated with acquired TKI resistance. Anti-CD70 antibody drug conjugates (ADCs) and CD70-targeting CAR T cell and CAR NK cells show potent activity against EGFR TKI resistant cells and DTPCs. These results identify CD70 as a therapeutic target for EGFR mutant tumors with acquired EGFR TKI resistance that merits clinical investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2023.01.007

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 51

  1. Chung, 2011, Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs, Lung Cancer, 73, 176, 10.1016/j.lungcan.2010.11.011 · DOI · Paper page
  2. Uramoto, 2010, Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma, Anticancer Res., 30, 2513
  3. Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238 · DOI · Paper page
  4. Pao, 2005, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions, J. Clin. Oncol., 23, 2556, 10.1200/JCO.2005.07.799 · DOI · Paper page
  5. Nishino, 2017, Osimertinib in EGFR T790M-positive lung cancer, N. Engl. J. Med., 376, 1992, 10.1056/NEJMc1703339 · DOI
  6. Ou, 2017, Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non-small cell lung cancer, J. Thorac. Oncol., 12, 145, 10.1016/j.jtho.2016.09.131 · DOI
  7. Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin. Cancer Res., 22, 4585, 10.1158/1078-0432.CCR-15-3101 · DOI · Paper page
  8. Negrao, 2018, Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.9052 · DOI
  9. Negrao, 2021, Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer, J. Immunother. Cancer, 9
  10. Mazieres, 2019, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann. Oncol., 30, 1321, 10.1093/annonc/mdz167 · DOI · Paper page
  11. Byers, 2013, An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin. Cancer Res., 19, 279, 10.1158/1078-0432.CCR-12-1558 · DOI · Paper page
  12. Nolte, 2009, Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology, Immunol. Rev., 229, 216, 10.1111/j.1600-065X.2009.00774.x · DOI · Paper page
  13. Craddock, 2013, Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia, Leukemia, 27, 1028, 10.1038/leu.2012.312 · DOI
  14. Bowman, 1994, The cloning of CD70 and its identification as the ligand for CD27, J. Immunol., 152, 1756, 10.4049/jimmunol.152.4.1756 · DOI
  15. Chen, 2014, Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, Nat. Commun., 5, 5241, 10.1038/ncomms6241 · DOI · Paper page
  16. Kashima, 2021, Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer, Cancer Res., 81, 4835, 10.1158/0008-5472.CAN-20-2811 · DOI
  17. Roper, 2020, Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer, Cell Rep. Med., 1
  18. Chua, 2021, Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities, Clin. Cancer Res., 27, 5939, 10.1158/1078-0432.CCR-20-4607 · DOI
  19. Aigner, 2007, The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity, Oncogene, 26, 6979, 10.1038/sj.onc.1210508 · DOI · Paper page
  20. Sánchez-Tilló, 2010, ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1, Oncogene, 29, 3490, 10.1038/onc.2010.102 · DOI · Paper page
  21. Shen, 2016, TGF-beta1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN, Biomed. Pharmacother., 77, 1, 10.1016/j.biopha.2015.10.018 · DOI
  22. Yang, 2014, TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma, Leukemia, 28, 1872, 10.1038/leu.2014.84 · DOI · Paper page
  23. Becker, 2019, CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC, Cancer Res., 79, 4439, 10.1158/0008-5472.CAN-19-0024 · DOI
  24. Riether, 2017, CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia, J. Exp. Med., 214, 359, 10.1084/jem.20152008 · DOI · Paper page
  25. Lu, 2005, Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs, J. Immunol., 174, 6212, 10.4049/jimmunol.174.10.6212 · DOI · Paper page
  26. Riether, 2020, Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents, Nat. Med., 26, 1459, 10.1038/s41591-020-0910-8 · DOI · Paper page
  27. Arens, 2004, Signaling through CD70 regulates B cell activation and IgG production, J. Immunol., 173, 3901, 10.4049/jimmunol.173.6.3901 · DOI
  28. García, 2004, Signalling via CD70, a member of the TNF family, regulates T cell functions, J. Leukoc. Biol., 76, 263, 10.1189/jlb.1003508 · DOI
  29. Tricker, 2015, Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer, Cancer Discov., 5, 960, 10.1158/2159-8290.CD-15-0063 · DOI · Paper page
  30. Law, 2006, Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates, Cancer Res., 66, 2328, 10.1158/0008-5472.CAN-05-2883 · DOI
  31. Pich, 2016, Melanoma-expressed CD70 is involved in invasion and metastasis, Br. J. Cancer, 114, 63, 10.1038/bjc.2015.412 · doi:10.1038/bjc.2015.412
  32. Ryan, 2010, Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75, Br. J. Cancer, 103, 676, 10.1038/sj.bjc.6605816 · DOI
  33. Liu, 2018, Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs, Breast Cancer, 25, 706, 10.1007/s12282-018-0880-6 · DOI
  34. Jacobs, 2015, Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer, Oncotarget, 6, 13462, 10.18632/oncotarget.3880 · DOI
  35. Loenen, 1992, The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis, Eur. J. Immunol., 22, 447, 10.1002/eji.1830220224 · DOI · Paper page
  36. Kato, 2007, Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells, Exp. Hematol., 35, 434, 10.1016/j.exphem.2006.10.018 · doi:10.1016/j.exphem.2006.10.018
  37. Hintzen, 1991, A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex, J. Immunol., 147, 29, 10.4049/jimmunol.147.1.29 · DOI
  38. Jacobs, 2015, CD70: an emerging target in cancer immunotherapy, Pharmacol. Ther., 155, 1, 10.1016/j.pharmthera.2015.07.007 · DOI · Paper page
  39. Silence, 2014, ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade, mAbs, 6, 523, 10.4161/mabs.27398 · DOI
  40. Wischhusen, 2002, Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma, Cancer Res., 62, 2592
  41. Wang, 2012, Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma, Cancer Res., 72, 6119, 10.1158/0008-5472.CAN-12-0588 · DOI · Paper page
  42. Fukuda, 2019, Epithelial-to-Mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status, Cancer Res., 79, 1658, 10.1158/0008-5472.CAN-18-2052 · DOI
  43. Győrffy, 2013, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer, PLoS One, 8, 10.1371/journal.pone.0082241 · DOI · Paper page
  44. Mak, 2016, A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition, Clin. Cancer Res., 22, 609, 10.1158/1078-0432.CCR-15-0876 · DOI · Paper page
  45. Tang, 2013, A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients, Clin. Cancer Res., 19, 1577, 10.1158/1078-0432.CCR-12-2321 · DOI · Paper page
  46. Edgar, 2002, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids Res., 30, 207, 10.1093/nar/30.1.207 · DOI · Paper page
  47. Byers, 2009, Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer, Clin. Cancer Res., 15, 6852, 10.1158/1078-0432.CCR-09-0767 · DOI · Paper page
  48. Nanjundan, 2010, Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence, J. Thorac. Oncol., 5, 1894, 10.1097/JTO.0b013e3181f2a266 · DOI · Paper page
  49. Arbiser, 1997, Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways, Proc. Natl. Acad. Sci. USA, 94, 861, 10.1073/pnas.94.3.861 · DOI · Paper page
  50. Dang, 2012, Soluble CD27 induces IgG production through activation of antigen-primed B cells, J. Intern. Med., 271, 282, 10.1111/j.1365-2796.2011.02444.x · DOI
  51. Lin, 2014, Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition, BMC Genom., 15, 1079, 10.1186/1471-2164-15-1079 · DOI

Cited by

See all 106

Metadata

Authors
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., Yu, X., Ren, X., Diao, L., Shen, L., Wang, Q., Zhang, M., Robichaux, J. P., Shi, C., Pfeil, A. N., Tran, H., Gibbons, D. L., Bock, J., Wang, J., Minna, J. D., Kobayashi, S. S., Le, X., & Heymach, J. V.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2023-02
Volume
41
Issue
2
Pages
340-355.e6
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4320487352
Cited by
106
References
24
FWCI
16.84
Type
journal article
Language
en
Open access
bronze
Funders
  • National Cancer Institute (5 P50 CA070907, CA016672, 1R01CA190628, 1R01CA234183-01A1, 1R01CA240257, 1R01CA247975, 1R50CA265307)
  • Cancer Prevention and Research Institute of Texas (RP120348, RP170002)
  • Emerson Collective
  • National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.